Document is current
Any future updates will be listed below
-
Authors
Solana-Altabella, Antonio https://orcid.org/0000-0002-8804-3878
Rodríguez-Veiga, Rebeca https://orcid.org/0000-0003-2139-8540
Martínez-Cuadrón, David https://orcid.org/0000-0001-7540-4091
Montesinos, Pau https://orcid.org/0000-0002-3275-5593
-
Funding
Funding for this research was provided by:
Fundación para la Investigación del Hospital Universitari La Fe (2020-017-1)
Instituto de Salud Carlos III (CM23/00148)
- License Information
-
More Information
Article History
Received: 29 May 2024
Accepted: 10 July 2024
First Online: 16 August 2024
Declarations
:
: PM has served in a consultancy position for Menarini/Stemline, Gilead, Otsuka, Kura Oncology, AbbVie, Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, BeiGene, Astellas, Pfizer, Incyte, Takeda, Ryvu, and Nerviano; reports receiving research funding from AbbVie, Bristol Myers Squibb, Jazz Pharmaceuticals, Menarini/Stemline, Novartis, Pfizer, and Takeda; and has served on a speakers bureau for AbbVie, Astellas, Bristol Myers Squibb, Gilead, Jazz Pharmaceuticals, and Pfizer.ASA, RRV and DMC declare no conflict of interest.
